Hepatocellular Carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published in 2018 – Ann Oncol (2018) 29 (Suppl 4): iv238–iv255.
Authors: A. Vogel, A. Cervantes, I. Chau, B. Daniele, J. Llovet, T. Meyer, J.-C. Nault, U. Neumann, J. Ricke, B. Sangro, P. Schirmacher, C. Verslype, C. J. Zech, D. Arnold & E. Martinelli, on behalf of the ESMO Guidelines Committee

A correction has been published - Annals of Oncology, mdy510
NB: The changes noted in the above correction have been incorporated into the manuscript displayed below. 

The 2018 ESMO Clinical Practice Guidelines on hepatocellular carcinoma (HCC) are conceived to provide the standard approach to diagnosis and local and systemic treatment of HCC. New recommendations are provided regarding the locoregional management and the systemic treatment with lenvatinib, regorafenib, cabozantinib, ramucirumab and the anti-PD-1 antibodies (nivolumab and pembrolizumab) for advanced HCC. Also included are new diagnosis systems and treatment algorithms.

Download the PDF from Annals of Oncology